1201693-66-4

Basic information

• Product Name: 4-{2-[4-(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-3-methoxy-benzoylamino]-ethyl}-piperazine-1-carboxylic acid tert-butyl ester
• Synonyms: 4-{2-[4-(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-3-methoxy-benzoylamino]-ethyl}-piperazine-1-carboxylic acid tert-butyl ester
• CAS NO: 1201693-66-4
• Molecular Weight: 658.749
• Mol File: 1201693-66-4.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 4-{2-[4-(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-3-methoxy-benzoylamino]-ethyl}-piperazine-1-carboxylic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-{2-[4-(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-3-methoxy-benzoylamino]-ethyl}-piperazine-1-carboxylic acid tert-butyl ester(1201693-66-4)
• EPA Substance Registry System: 4-{2-[4-(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-3-methoxy-benzoylamino]-ethyl}-piperazine-1-carboxylic acid tert-butyl ester(1201693-66-4)

Safety Data

• Hazardous Substances Data: 1201693-66-4(Hazardous Substances Data)

Upstream product

• 1062243-48-4 4-(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-3-methoxy-benzoic acid 
• 192130-34-0 tert-butyl 4-(2-aminoethyl)piperazine-1-carboxylate 

Downstream Products

• 1201691-44-2 4-(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-3-methoxy-N-(2-piperazin-1-yl-ethyl)-benzamide 

Relevant articles and documents

HALO-SUBSTITUTED PYRIMIDODIAZEPINES

The present invention provides PLK1 inhibitor compounds of formula I: useful in the treatment or control of cell proliferative disorders, particularly oncological disorders. These compounds and formulations containing such compounds may be useful in the treatment or control of solid tumors, such as, for example, breast, colon, lung and prostate tumors and other oncological diseases such as non-Hodgkin's lymphomas. Also provided are intermediate compounds useful in the synthesis of compounds of formula I.